Diplomat Pharmacy Inc. (NYSE:DPLO) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are covering the company. Three research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.80.
A number of brokerages recently issued reports on DPLO. Credit Suisse Group AG downgraded Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $18.00 to $13.00 in a report on Wednesday, November 23rd. TheStreet downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Thursday, November 3rd. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Diplomat Pharmacy in a report on Thursday, November 3rd. Raymond James Financial Inc. reaffirmed a “market perform” rating on shares of Diplomat Pharmacy in a report on Thursday, November 3rd. Finally, Barclays PLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Diplomat Pharmacy in a report on Thursday, November 3rd.
In related news, EVP Atheer A. Kaddis sold 20,000 shares of the stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $30.12, for a total transaction of $602,400.00. Following the sale, the executive vice president now owns 20,000 shares of the company’s stock, valued at $602,400. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 35.40% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of DPLO. Capital Research Global Investors bought a new stake in Diplomat Pharmacy during the third quarter worth approximately $28,761,000. Capital World Investors raised its stake in Diplomat Pharmacy by 41.3% in the second quarter. Capital World Investors now owns 1,966,600 shares of the company’s stock worth $68,831,000 after buying an additional 575,000 shares during the last quarter. BlackRock Fund Advisors raised its stake in Diplomat Pharmacy by 18.3% in the third quarter. BlackRock Fund Advisors now owns 3,180,902 shares of the company’s stock worth $89,097,000 after buying an additional 492,922 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Diplomat Pharmacy by 26.8% in the second quarter. TimesSquare Capital Management LLC now owns 1,403,455 shares of the company’s stock worth $49,121,000 after buying an additional 296,500 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Diplomat Pharmacy by 9.5% in the second quarter. Vanguard Group Inc. now owns 3,334,010 shares of the company’s stock worth $116,690,000 after buying an additional 289,571 shares during the last quarter. 77.02% of the stock is currently owned by institutional investors and hedge funds.
Diplomat Pharmacy (NYSE:DPLO) traded up 1.8337% during trading on Monday, hitting $15.3056. 366,086 shares of the stock traded hands. Diplomat Pharmacy has a 12 month low of $12.47 and a 12 month high of $38.94. The stock has a market cap of $1.02 billion, a P/E ratio of 31.5579 and a beta of 1.21. The firm’s 50-day moving average is $21.08 and its 200-day moving average is $30.03.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.21 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.24 by $0.03. The business earned $1.18 billion during the quarter, compared to analyst estimates of $1.26 billion. Diplomat Pharmacy had a net margin of 0.77% and a return on equity of 10.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. On average, analysts forecast that Diplomat Pharmacy will post $0.84 EPS for the current year.